The Asia Pacific Cancer Biomarker Market is expected to grow at a strong CAGR of 14% during the forecast period (2022-20230). The Asia Pacific region is anticipated to grow with a significant CAGR during the forecast period with the surge in geriatric population and associated increase in the incidences . According to the stats from the United Nations, the geriatric population in APAC is expected to reach 1.3 billion by 2050, accounting for around 60% of the world’s elderly population. The surge in geriatric population will also lead to associated surge in the prevalence of cancer. According to the report titled “Cancer statistics in China and U.S., 2022: profiles, trends, and determinants” published in February 2022, compared to the 4,568,754 new cancer cases in China in 2020, the predicted number of new cancer cases for 2022 is 4,820,000. This increase in new cases will directly increase the demand for cancer therapy, thus helping in the growth of the market during the study period.

Access sample report (including graphs, charts, and figures): https://univdatos.com/report/cancer-biomarker-market/get-a-free-sample-form.php?product_id=38906

China is expected to be the largest market owing to its large population and growing economy. The key players are rapidly investing to launch their products in the APAC region, thus boosting the market growth. For instance, in October 2022, The Garvan Institute of Medical Research in Australia discovered a new biomarker for prostate cancer that could lead to better diagnosis and treatment for men with the aggressive form of this disease.

FIG. 1 APAC Cancer Biomarker Market Revenue (2020-2030)- USD Mn

news.png

Based on type, the market is segmented into protein, genetic biomarker, and glycol-biomarkers. The genetic biomarkers held a dominant share of the market in 2021 as they are utilized on a large scale and are very effective. These biomarkers are exclusively utilized for managing and diagnosing cancer, thus driving segmental growth.

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://univdatos.com/report/cancer-biomarker-market/

By indication, the market is segmented into prostate cancer, breast cancer, lung cancer, colorectal cancer, cervical cancer, stomach cancer, liver cancer, and others. The lung cancer segment is anticipated to grow with a significant CAGR during the forecast period. It is mainly attributed to the surge in the incidences of lung cancer and the associated rise in research and development activities. For instance, in February 2023, researchers at AIIMS created e-Nose for the detection of lung cancer. Further, in October 2020, RIKEN, iProgen Biotech Inc., and iPrime Therapeutics Co., entered into a collaboration to identify biomarkers unique to lung cancer cells suitable for targeted therapeutics.

Based on profiling technologies, the market is segmented into omics technologies, imaging technologies, immunoassays, bioinformatics, and cytogenetics. The omics held a significant share of the market in 2021. Omics technology is highly effective in the early diagnosis of cancer. Furthermore, novel development in profiling technologies for cancer biomarkers is also having a positive impact on the growth of the market.

Based on application, the market is segmented into drug discovery & development, diagnostics, prognostics, and others. The drug discovery & development is expected to grow with significant CAGR during the forecast period. The segment is growing due to the growing awareness among healthcare practitioners about cancer biomarkers. In addition, the demand for personalized medicines is also growing. One of the key factors driving the segment growth is approvals on diagnostic tests are quite easy nowadays which is creating demand for cancer biomarkers.   

Global Cancer Biomarker Market Segmentation

Market Insight, by Type

  • Protein
  • Genetic Biomarker
  • Glyco-Biomarkers

Market Insights, by Indication

  • Prostate Cancer
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Stomach Cancer
  • Liver Cancer
  • Others

Market Insights, by Profiling Technologies

  • Omics Technologies
  • Imaging Technologies
  • Immunoassays
  • Bioinformatics
  • Cytogenetics

Market Insights, by Application

  • Drug Discovery & Development
  • Diagnostics
  • Prognostics
  • Others

Market Insight, by Region

  • North America U.S.
  •  Canada
  •  Rest of North America
  • EuropeGermany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
  • APACChina
  • Japan
  • India
  • Rest of APAC
  • Rest of the World

Top Company Profiles

  • Qiagen
  • Abbott Laboratories Inc.
  • Agilent Technologies
  • Merck Millipore
  • Biomerieux
  • Quest Diagnostics
  • F. Hoffmann-La Roche Ltd
  • Hologic Inc.
  • Illumina Inc.
  • Thermo Fisher Scientific